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COVAX: A Primer to International Efforts in
Vaccine Distribution and Inequities
DIANE DESIERTO

I have a slightly different view from Dr. Oke in regard to his
doubts regarding the utility of a waiver. To the extent that the
precedent that we are looking at is whether or not there could be a
waiver for countries that lack domestic manufacturing capabilities, to
instead import a cheaper generic drug of the Covid vaccines that
could be produced in other countries, mainly the particular hubs, such
as in India and China, that is still an open question, and part of the
proposal that is up before the TRIPS council involves that dimension
and that aspect of the waiver as well.
But I want us to take a step back and focus on where we are at
the moment with respect to the negotiations and deliberations that
states are undertaking with respect to the possibilities of such a
waiver, and the relaxation generally of intellectual property rules. If
we look internally to intellectual property law, it might seem that
there are quite insurmountable political differences, as well as legal
hurdles, to carry us over the threshold to a waiver. My source for
looking at this, these particular obligations on the part of states as
they undertake negotiations like these, emanate primarily from two
fundamental norms, both in treaty law and in the Charter of the
United Nations, and I am talking about the obligations on nondiscrimination and the obligations on equality that are enshrined in
both in the Charter of the United Nations, as well as in the Covenant
on Economic, Social and Cultural Rights and the Covenant on Civil
and Political Rights.
Before I elaborate on these two norms and explain why they
should be the predicate basis for how states are negotiating solutions
in regard to the TRIPS framework and vaccine distribution, I would
like to show you some data from the Civic tracker. The civic freedom
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tracker was set up in concert and in collaboration with the
Commission of The Office of the High Commissioner for Human
Rights and you can see that basically the entire world is almost under
a state of emergency with varying degrees of lockdowns and
measures that are in place and affect privacy, freedom of assembly
and expression. This is what makes the situation radically different
from previous pandemics. In this pandemic, along with an attempt to
try and make determinations for the effectiveness of vaccines, and the
equitableness of the distribution, we have a climate with relative non
transparency as a result of prevailing restraints on Civil and Political
freedoms and simultaneous challenges with respect to the evaluation
of compliance with economic, social, cultural rights. At the outset
this should make it eminently clear that even trying to make a legal
assessment of what is equitable, what is non-discriminatory, what is
equal, within the requirements of international law is difficult to do in
a climate where information is purposely suppressed; where
transparency, either from the private sector distributors of the
vaccine, or from host governments that are purchasing the vaccine, or
even from a facility such as Covax, transparency is not really
forthcoming. In this particular climate we have to acknowledge that
many states are making decisions, largely out of some sense of either
state driven interests or vaccine nationalism, but also under a climate
of lack of data.
In regard to what the particular vulnerabilities are, region to
region, country to country, county to county, I want to move to this
other chart which tells us the number of people who have been fully
vaccinated against covid 19 on a worldwide basis. If we see in
particular where the gray areas are, these are areas, particularly in the
developing world, in Sub Saharan Africa, in South and Southeast
Asia, and East Asia, as well as parts of Latin America, the data is not
forthcoming as to who has actually received the vaccine, and the
extent to which there has been uniform, transparent reportage and
exchange of information in regard to the efficacy of the vaccine and
whether or not we’re dealing with variants. The same website also
gives a relatively clear picture of why it is hard to try and make out a
case of non-discrimination in regard to vaccine policies, and why
there is also a challenge in regard to equality as a norm of
international law under human rights law when we are talking about
access to vaccines. It is the assessment of vulnerabilities that
determines whether or not certain populations get access to the
vaccine faster than other populations, and that assessment of
vulnerability is contentious. To begin with, the assessment cuts
across different healthcare systems, different systems with respect to
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the multi-dimensional aspects of health, with respect to social
determinants of health, as well as physical, physiological, and
medical determinants of health. These systems vary country to
country, and yet we are proceeding on a premise that if we look at the
hard numbers as to which countries have been getting doses of the
vaccine, that is enough to frame our understanding of whether the
legal criteria for non-discrimination and equality are being met.
It is not just about the raw numbers of whether vaccines are
being allocated, but in targeting access for the vaccines, how are
vulnerabilities being assessed consistent with the right to the highest
attainable standard of physical and mental health, consistent with our
understanding of the overall determinants, social as well as
physiological, of the right to health. Is it enough to say that if we look
at the number of covid fatalities vis-a-vis the number of covid
incidences, that is enough for policymakers to determine what
vaccines should go to a certain quantum or to a particular area? A lot
of the policy making, unfortunately, has come after the fact of law,
and law has largely been left at the wayside when it comes to the
framework and the distribution and development of vaccines, and the
ongoing assessment of whether or not we are looking at short,
medium or long-term distribution of these vaccines, which is why I
think it is perfectly relevant to think about a waiver at this time.
When the latest estimates say that we will not receive global
herd immunity until at least 2023, and when most of the world is
under a state of emergency, we have to remember that not everybody
is experiencing Covid-19 in the way that the United States is
experiencing it. We are looking at protracted situations of lockdowns,
protracted vulnerabilities in health care systems and infrastructures,
protracted situations of extreme poverty where we now have 290
million people being pushed further into extreme poverty and being
told to wait their turn simply because that is how it is in the
international system; that is not in itself a situation that comports with
the legal criteria for non-discrimination and equality.
So let me turn to the legal criteria. Why do I focus on nondiscrimination and equality? If we think of the non-discrimination
norm, which is present within Charter law, specifically in article 55
of the Charter of the United Nations, and in article 1 of the Covenants
on Civil and Political Rights and article 2 the Covenant on Economic,
Social, Cultural rights, and which calls for all member states to
respect human rights and fundamental freedoms. There are four
essential criteria to determine non-discrimination, and I have argued
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in previous work that this is just supposed to be the floor. When it
comes to the intersectional understanding of compliance with human
rights, non-discrimination requires proof of differential treatment.
Further, that differential treatment should be based on a prohibited
ground of discrimination, which include race, sex, gender, education,
birth status, language, religion, among others. The third element is
that that differential treatment which is based on a prohibited ground
of discrimination must result in the deprivation of the enjoyment of a
certain human right. And lastly, there must be specific discriminatory
intent in the measure. This last aspect, the discriminatory intent, is
often the most difficult to prove, which is why in circumstances when
you have non-discrimination taking place, especially in the climate
that I have laid out where there are states of emergency, difficulty of
access to human rights defenders, difficulty of access to courts, let
alone leaving one’s house given multiple checkpoints, it is difficult to
exact accountability through the non-discrimination norm by going to
court. If we were to think about it at the individual or community
level where inter-sectional disparities occur, where those who are
most affected by Covid-19 cut across many of the markers of
discrimination, women, women of color, children, persons with
disabilities, these are entities that are the least empowered to be able
to seek access to courts before their own jurisdictions, let alone courts
in other jurisdictions to gain redress for the discriminatory treatment
in regard to the provision of health services, and specifically access to
Covid-19 vaccines.
If we can already see that it will be a futile exercise on the part
of individuals to try and seek recourse under this climate of states of
emergency around the world, what, then, is the counterpart obligation
of these states that are tasked to respect the duty of nondiscrimination? I argue that that duty of non-discrimination imposes
deeper burdens on them when they are negotiating at the World
Trade Organization in regard to this particular appeal for waivers.
Because in this sense, we’re not just looking at trade law, we’re
looking at their existing duties of cooperation under the Charter of
the United Nations, their existing duties of cooperation and nondiscrimination, as well as equality, under human rights law, to which
all, or at least 175 countries in the world, including all the vaccine
producing states are a party to these treaties, as well as to the
counterpart obligations erga omnes and jus cogen norms that may be
verily associated with human rights norms. And yet, it is hard to
make the case, as it stands, because everybody is living in a state of
emergency and to the extent that governments have been appealing to
a wider sense of executive discretion during a state of emergency, it

3_DESIERTO VOL. 36_14 (DO NOT DELETE)

18

MARYLAND JOURNAL OF INTERNATIONAL LAW

11/14/2021 12:50 PM

[Vol. 36:1

is easy to compartmentalize the debate and think about this as just a
question of whether or not TRIPS and the requirements for a waiver
are met. It is easy to compartmentalize that and think that
participation in an international organization should only be about the
founding treaties, or the organic treaties, the lex specialis that governs
that particular international organization. But this is why I go back to
the Charter of the United Nations and the fundamental duties to
cooperate, that exist regardless of what the lex specialis is: these are
continuing obligations.
Unlike in previous pandemics and previous epidemiological
situations, the unique challenge to Covid-19 is that the assessments of
vulnerability are taking place at a time when information is not open,
when information is hard to obtain on the ground and when
assessments of vulnerability can very readily differ jurisdiction to
jurisdiction. If this is the situation that we have before us, why are we
not in thinking about creating proposals, such as Covax, which aims
to have at least 20% of populations in the developing world
vaccinated; Why are we thinking of these programs quite
hermetically, in isolation from the continuing general international
law obligations of states? It makes it look like vaccine development
and distribution is more of a humanitarian act, rather than an
international legal obligation that is not optional on the part of states.
So much of the framing of the entire issue of vaccine distribution is a
framing of equity for the sake of equity, not as a legal norm but as an
appeal to aid on the part of the developing world. This, however,
should be an appeal to the rule of law, which has been left by the
wayside with the kind of rhetoric that we have seen in the framing of
vaccine development, distribution and access.

